# US 2026/0021043 A1 · Starch-based hydrogel for administration of therapeutic anticancer agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0021043 A1
- Document ID: US20260021043A1
- Status: Published application
- Kind: A1
- Application number: 19/271,610
- Filed: 2025-07-16
- Published: 2026-01-22
- Earliest claimed: 2024-07-16
- Inventors: Elizabeth Diana Barker
- Web page: https://patentgrep.com/patent/US20260021043A1

## CPC

- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 41/0095: {Boron neutron capture therapy, i.e. BNCT, e.g. using boronated porphyrins}
- A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K 51/1213: {Semi-solid forms, gels, hydrogels, ointments, fats and waxes that are solid at room temperature}
- A61K 2121/00: Preparations for use in therapy
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A starch-based injectable hydrogel system for localized cancer treatment. The pre-formed hydrogel delivers chemotherapeutic drugs (such as doxorubicin) and/or medical radionuclides directly to tumor sites while minimizing systemic exposure. The composition uses dimethyl sulfoxide as a solvent and can be stored in pre-filled syringes for clinical use. Key advantages include >90% drug retention, sustained local delivery, and compatibility with image-guided injection techniques. The system is particularly suitable for pediatric brain tumors and other solid tumors requiring localized high-dose therapy.

## Claims

### Claim 1

A composition comprising:
a starch-derived polymer forming a hydrogel matrix;
a solvent comprising dimethyl sulfoxide, an aqueous solvent selected from phosphate buffered saline or sodium chloride solution, or a combination thereof; and
a chemotherapeutic agent comprising
doxorubicin in its free base form or
a compound that is insoluble in water and substantially soluble in dimethyl sulfoxide,
wherein the composition may be a pre-formed injectable hydrogel formulation comprising the therapeutic agent prior to administration.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the hydrogel comprises a crosslinking agent comprising d-glucaric acid; optionally wherein the starch-derived polymer comprises a mixture of high molecular weight and low molecular weight amylopectin species; optionally wherein the hydrogel is synthesized in a solvent system comprising dimethyl sulfoxide and water; and optionally wherein the hydrogel is synthesized without initiators or catalysts.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the hydrogel retains at least about 90% of the therapeutic agent under physiological conditions; optionally wherein the retention is maintained over a period of at least about 24 hours; optionally wherein the retention is determined by liquid chromatography, ultraviolet-visible spectroscopy, or plasma pharmacokinetic analysis; and optionally wherein the therapeutic agent comprises doxorubicin in its free base form.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the chemotherapeutic agent penetrates at least about 10 mm into surrounding tissue from an intratumoral injection site; optionally wherein the penetration depth is determined by fluorescence imaging or histological analysis;
optionally wherein the chemotherapeutic agent comprises doxorubicin in its free base form; and optionally wherein the composition is administered to a pediatric brain tumor.

### Claim 5 (depends on 1)

The composition of claim 1, wherein systemic exposure to the chemotherapeutic agent is reduced relative to an equivalent intravenous dose; optionally wherein the systemic exposure is determined by liquid chromatography-mass spectrometry; and optionally wherein the chemotherapeutic agent comprises doxorubicin in its free base form.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the hydrogel is sterilized and stored in a pre-filled syringe suitable for intratumoral injection; optionally wherein the syringe is configured for single use; optionally wherein the syringe is compatible with image-guided delivery techniques; and optionally wherein the hydrogel is stable for a storage period of at least about four weeks.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the composition is configured for administration to a pediatric solid tumor; optionally wherein the pediatric solid tumor comprises a brain tumor; optionally wherein the brain tumor comprises a medulloblastoma or glioma; and optionally wherein the composition is administered during or after surgical resection.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the chemotherapeutic agent comprises a lipophilic compound; optionally wherein the lipophilic compound is doxorubicin in its free base form; optionally wherein the lipophilic compound has a water solubility of less than about 1 mg/mL at 25° C.; and optionally wherein the solvent system enables solubilization and sustained retention of the lipophilic compound without precipitation.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the hydrogel is pre-formed and stable for storage as an injectable formulation; optionally wherein the formulation is maintained as a gel throughout storage and administration; optionally wherein the hydrogel is stable for at least about four weeks; and optionally wherein no gelling, mixing, or reconstitution step is required prior to injection.

### Claim 10 (depends on 1)

The composition of claim 1, wherein the starch-derived hydrogel comprises a boron-containing therapeutic agent suitable for boron neutron capture therapy; optionally wherein the boron-containing therapeutic agent comprises a carborane, a boronic acid, or a boronated phenylalanine analog; and optionally wherein the hydrogel is retained at a tumor site prior to neutron exposure.

### Claim 11 (depends on 1)

The composition of claim 1, wherein the chemotherapeutic agent comprises a compound that is insoluble in water and soluble in dimethyl sulfoxide; optionally wherein the agent comprises a topoisomerase inhibitor or an anthracycline compound.

### Claim 12

A composition comprising:
a starch-based hydrogel comprising a polymer matrix;
a solvent comprising dimethyl sulfoxide, an aqueous solvent selected from phosphate buffered saline or sodium chloride solution, or a combination thereof; and
a radionuclide selected from
an alpha-emitting radionuclide,
a beta-emitting radionuclide, or
a gamma-emitting radionuclide,
wherein the composition is a pre-formed injectable hydrogel formulation comprising the radionuclide prior to administration.

### Claim 13 (depends on 12)

The composition of claim 12, wherein:
the alpha-emitting radionuclide is selected from actinium-225, astatine-211, bismuth-213, lead-212, radium-223, terbium-149, thorium-227, thorium-226, fermium-225, or uranium-230;
the beta-emitting radionuclide is selected from lutetium-177, yttrium-90, samarium-153, rhenium-186, strontium-89, iodine-131, or phosphorus-32; and
the gamma-emitting radionuclide is selected from technetium-99m, indium-111, iodine-123, iodine-124, gallium-67, gallium-68, thallium-201, cobalt-57, krypton-81m, or xenon-133.

### Claim 14 (depends on 12)

The composition of claim 12, wherein the hydrogel retains at least about 90% of the radionuclide upon formation; optionally wherein the encapsulation efficiency is determined by ultraviolet-visible spectroscopy or dialysis analysis; optionally wherein the radionuclide comprises cerium-144; and optionally wherein the starch polymer chains are crosslinked using d-glucaric acid.

### Claim 15 (depends on 12)

The composition of claim 12, wherein the hydrogel retains at least about 90% of the radionuclide over a period of at least about 7 days under physiological conditions;
optionally wherein the retention is determined by dialysis or static diffusion testing;
optionally wherein the radionuclide comprises cerium-144 or cerium-141; and optionally wherein the hydrogel is maintained under aqueous conditions at 37° C. during testing.

### Claim 16 (depends on 12)

The composition of claim 12, wherein the hydrogel is sterilized and stored in a pre-filled syringe suitable for intratumoral injection; optionally wherein the syringe is configured for single use and radiation-shielded storage; optionally wherein the composition remains physically stable in the syringe for at least about four weeks; and optionally wherein the syringe is compatible with image-guided delivery techniques.

### Claim 17 (depends on 12)

The composition of claim 12, wherein systemic radioactivity resulting from administration of the composition is below detectable levels at 24 hours post-injection; optionally wherein the systemic radioactivity is assessed by gamma counting, scintigraphy, or radiometric detection of blood plasma; optionally wherein the radionuclide comprises cerium-144; and optionally wherein the composition is administered via intratumoral injection to a solid tumor.

### Claim 18 (depends on 12)

The composition of claim 12, wherein the composition is configured for administration to a pediatric solid tumor; optionally wherein the pediatric solid tumor comprises a brain tumor; optionally wherein the brain tumor comprises a medulloblastoma or ependymoma; and optionally wherein the composition is administered locally during or after surgical resection of the tumor.

### Claim 19 (depends on 12)

The composition of claim 12, wherein the radionuclide is selected from actinium-225, thorium-227, lutetium-177, or terbium-161; optionally wherein the radionuclide is selected based on its emission of alpha particles, beta particles, or Auger electrons; optionally wherein the composition comprises a chelator-free encapsulation of the radionuclide within the hydrogel matrix; and optionally wherein the composition is configured for site-specific delivery to a solid tumor.

### Claim 20 (depends on 12)

The composition of claim 12, wherein the radionuclide comprises a gamma-emitting or positron-emitting radionuclide suitable for diagnostic imaging; optionally wherein the radionuclide comprises cerium-141, lutetium-177, or terbium-161; optionally wherein the composition enables detection by scintigraphy, PET, or SPECT imaging; and optionally wherein the composition is used to monitor intratumoral distribution following injection.

### Claim 21 (depends on 12)

The composition of claim 12, wherein the hydrogel is physically and chemically stable for at least about four weeks; optionally wherein the radionuclide remains encapsulated without significant leakage during the storage period; optionally wherein the composition is maintained in a sealed container without requiring reconstitution prior to administration.

### Claim 22 (depends on 12)

The composition of claim 12, wherein the radionuclide comprises actinium-225 and the composition emits visible luminescence due to Cherenkov radiation under storage or post-injection conditions; optionally wherein the luminescence is used to confirm physical retention of the radionuclide in the hydrogel.

### Claim 23 (depends on 12)

The composition of claim 12, wherein the radionuclide is introduced into the hydrogel in the absence of a chelating agent; optionally wherein the composition provides in vivo retention of the radionuclide without use of diethylenetriaminepentaacetic acid (DTPA) or 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA).

### Claim 24

A composition comprising:
a starch-derived polymer forming a hydrogel matrix;
a solvent comprising dimethyl sulfoxide, an aqueous solvent selected from phosphate buffered saline or sodium chloride solution, or a combination thereof; and
a therapeutic agent selected from a chemotherapeutic agent or a radionuclide, wherein the composition is a pre-formed injectable hydrogel formulation that is formed prior to administration;
optionally wherein the chemotherapeutic agent comprises doxorubicin in its free base form or a compound that is insoluble in water and soluble in dimethyl sulfoxide; and
optionally wherein the radionuclide is selected from an alpha-emitting radionuclide, a beta-emitting radionuclide, or a gamma-emitting radionuclide, and comprises cerium-144, cerium-141, actinium-225, thorium-227, lutetium-177, terbium-161, yttrium-90, or indium-111.

### Claim 25 (depends on 24)

The composition of claim 24, wherein the therapeutic agent comprises both a chemotherapeutic agent and a radionuclide; optionally wherein the agents are co-retained in a single hydrogel matrix and administered simultaneously via a single intratumoral injection.

### Claim 26

A method of treating a solid tumor in a subject comprising:
administering to the solid tumor a composition comprising:
a starch-based hydrogel comprising a network of starch polymer chains crosslinked using a crosslinking agent;
a solvent comprising dimethyl sulfoxide; and
a therapeutic agent selected from a chemotherapeutic agent or a radionuclide, wherein the composition is a pre-formed injectable hydrogel formulation that is formed prior to administration; optionally wherein the chemotherapeutic agent comprises doxorubicin in its free base form; optionally wherein the radionuclide is selected from cerium-144, cerium-141, actinium-225, thorium-227, lutetium-177, or terbium-161;
and optionally wherein the tumor comprises a pediatric brain tumor.
